Fig. 2From: The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphomaAntibody–drug conjugates used in R/R DLBCLs. This picture shows the mechanisms and processes of antibody–drug conjugates in lymphoma patients. Once the antibody binds the target antigen on the tumor cell surface. The complex is rapidly endocytosed and transported to lysosomes, where the effector molecule MMAE is released into the cytoplasm leading to cell toxicity. ADC antibody–drug conjugateBack to article page